Multitarget Drug Discovery

Abstract

The multifunctional nature of currently incurable diseases has provided a strong background for the development of an innovative drug discovery strategy centred around the concepts of polypharmacology and dubbed multitarget drug discovery. It deals with the development of multitarget‐directed‐ligands (MTDLs), that is individual small molecules that, by simultaneously hitting multiple targets, should be able to tackle the compensatory mechanisms and robustness of complex disease networks, with the intrinsic benefits of a single‐molecule therapy. Starting from the 2000, multitarget drug discovery has emerged as an attractive alternative to the traditional single‐target approach. The elaboration of rationale medicinal chemistry strategies has allowed the discovery of already‐approved multitarget drugs and of many others that are in diverse development stages. It may thus become a constant feature of future drug discovery.

Key Concepts

  • One‐drug one‐target one‐disease paradigm has been dominating but is seen to have limitations.
  • The multifactorial nature of diseases supports the development of treatments able to modulate more than one target simultaneously, that is the so‐called polypharmacology.
  • There are three ways to achieve polypharmacology: drug cocktail, fixed‐dose combination, and multitarget‐drug.
  • Multitarget drugs can be superior to combinations thanks to a lower risk of drug–drug interactions and a simplification of the therapeutic regimen.
  • Multitarget drugs can be discovered either by rationale or by screening approaches.
  • Rationale approaches rely on the creation of hybrid drugs via linking, fusing and merging approaches.

Keywords: multitarget‐directed ligands; polypharmacology; rational drug design strategies; hybrid molecules; medicinal chemistry

Figure 1. Structures of imatinib, midostaurin, clozapine and safinamide multitarget drugs.
Figure 2. Possible clinical strategies for a polypharmacological therapy.
Figure 3. Design strategy for hybrid compounds.
Figure 4. Molecular examples of linking strategy: rational design of sultamicillin and edasalonexent.
Figure 5. Molecular example of the fused strategy: rational design of ladostigil.
Figure 6. Design of the dual BACE‐1/GSK‐3β inhibitors.
close

References

Baltzer B, Binderup E, von Daehne W, et al. (1980) Mutual pro‐drugs of beta‐lactam antibiotics and beta‐lactamase inhibitors. The Journal of Antibiotics 33: 1183–1192.

Barabási AL, Gulbahce N and Loscalzo J (2011) Network medicine: a network‐based approach to human disease. Nature Reviews Genetics 12: 56–68.

Bollag G, Tsai J, Zhang J, et al. (2012) Vemurafenib: the first drug approved for BRAF‐mutant cancer. Nature Reviews Drug Discovery 11: 873–886.

Bolognesi ML (2013) Polypharmacology in a single drug: multitarget drugs. Current Medicinal Chemistry 20: 1639–1645.

Bolognesi ML and Cavalli A (2016) Multitarget drug discovery and polypharmacology. ChemMedChem 11: 1190–1192.

Bolognesi ML (2019) Harnessing polypharmacology with medicinal chemistry. ACS Medicinal Chemistry Letters 10: 273–275.

Bottegoni G, Favia AD, Recanatini M and Cavalli A (2012) The role of fragment‐based and computational methods in polypharmacology. Drug Discovery Today 17: 23–34.

Cavalli A, Bolognesi ML, Minarini A, et al. (2008) Multi‐target‐directed ligands to combat neurodegenerative diseases. Journal of Medicinal Chemistry 51: 347–372.

Davis BJ and Roughley SD (2017) Chapter 11 ‐ Fragment‐based lead discovery. In: Goodnow RA Jr (ed.) Annual Reports in Medicinal Chemistry, pp 371–439. Elsevier: Cambridge, MA.

Decker M (2017) In: Decker M (ed.) Design of Hybrid Molecules for Drug Development. Elsevier: Amsterdam, Netherlands.

Donovan JM, Zimmer M, Offman E, Grant T and Jirousek M (2017) A novel NF‐κB inhibitor, edasalonexent (CAT‐1004), in development as a disease‐modifying treatment for patients with duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. The Journal of Clinical Pharmacology 57: 627–639.

Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology 4: 682–690.

Ivasiv V, Albertini C, Goncalves AE, Rossi M and Bolognesi ML (2019) Molecular hybridization as a tool for designing multitarget drug candidates for complex diseases. Current Topics in Medicinal Chemistry.

Iyengar R (2013) Complex diseases require complex therapies. EMBO Reports 14: 1039–1042.

Ji HF, Li XJ and Zhang HY (2009) Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO Reports 10: 194–200.

Kaufmann SH (2008) Paul Ehrlich: founder of chemotherapy. Nature Reviews Drug Discovery 7: 373.

Kibble M, Saarinen N, Tang J, et al. (2015) Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Natural Product Reports 32: 1249–1266.

Kumar AP, Lukman S and Nguyen MN (2019) Drug repurposing and multi‐target therapies. Reference Model in Life Sciences 780–791.

Levis M (2017) Midostaurin approved for FLT3‐mutated AML. Blood 129: 3403–3406.

Marzo A, Dal Bo L, Monti NC, et al. (2004) Pharmacokinetics and pharmacodynamics of sufinamide, a neuroprotectant wit antiparkinsonian and anticonvulsant activity. Pharmacological Research 50: 77–85.

Millan MJ (2006) Multi‐target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 110: 135–370.

Morphy R, Kay C and Rankovic Z (2004) From magic bullets to designed multiple ligands. Drug Discovery Today 9: 641–651.

Morphy R and Rankovic Z (2005) Designed multiple ligands. An emerging drug discovery paradigm. Journal of Medicinal Chemistry 48: 6523–6543.

Morphy R and Rankovic Z (2006) The physicochemical challenges of designing multiple ligands. Journal of Medicinal Chemistry 49: 4961–4970.

Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. Journal of Medicinal Chemistry 53: 1413–1437.

Morphy JR (2012) Chapter 10: The Challenges of Multi‐Target Lead Optimization. In: Designing Multi‐Target Drugs, pp 141–154. Royal Society of Chemistry: Cambridge, MA.

Mullin R (2014) Tufts study finds big rise in cost of drug development. Chemical and Engineering News 92: 6.

Pajouhesh H and Lenz GR (2005) Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2: 541–553.

Prati F, De Simone A, Armirotti A, et al. (2015a) 3,4‐Dihydro‐1,3,5‐triazin‐2(1H)‐ones as the first dual BACE‐1/GSK‐3β fragment hits against Alzheimer's disease. ACS Chemical Neuroscience 6: 1665–1682.

Prati F, De Simone A, Bisignano P, et al. (2015b) Multitarget drug discovery for Alzheimer's disease: triazinones as BACE‐1 and GSK‐3β inhibitors. Angewandte Chemie International Edition 54: 1578–1582.

Prati F, Cavalli A and Bolognesi ML (2016) Navigating the chemical space of multitarget‐directed ligands: from hybrids to fragments in Alzheimer's disease. Molecules 21: 466.

Preskorn SH and Flockhart D (2006) 2006 guide to psychiatric drug interactions. Primary Psychiatry 13: 35.

Rankovic Z (2015) CNS drug design: balancing physicochemical properties for optimal brain exposure. Journal of Medicinal Chemistry 58: 2584–2608.

Scannell JW, Blanckley A, Boldon H and Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery 11: 191–200.

Seritan AL (2008) How to prevent drug‐drug interactions with cholinesterase inhibitors. Current Psychiatry 7: 57.

Souers AJ, Leverson JD, Boghaert ER, et al. (2013) ABT‐199, a potent and selective BCL‐2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine 19: 202–208.

Van der Schyf CJ, Geldenhuys WJ and Youdim MB (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. Journal of Neurochemistry 99: 1033–1048.

Viayna E, Sabate R and Muñoz‐Torrero D (2013) Dual inhibitors of β‐amyloid aggregation and acetylcholinesterase as multi‐target anti‐Alzheimer drug candidates. Current Topics in Medicinal Chemistry 13: 1820–1842.

Viegas‐Junior C, Danuello A, Bolzani SV, Barreiro EJ and Fraga CA (2007) Molecular hybridization: a useful tool in the design of new drug prototypes. Current Medicinal Chemistry 14: 1829–1852.

Wager TT, Hou X, Verhoest PR and Villalobos A (2010) Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chemical Neuroscience 1: 435–449.

Wermuth CG (2004) Multitargeted drugs: the end of the “one‐target‐one‐disease” philosophy? Drug Discovery Today 9: 826–827.

Wink M (2008) Ecological roles of alkaloids. In: Fattorusso E and Taglialatela‐Scafati O (eds) Modern Alkaloids, pp 1–24. Wiley‐VCH Verlag GmbH Co. KGaA: Weinheim.

Youdim MB and Buccafusco JJ (2005) Multi‐functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends in Pharmacological Sciences 26: 27–35.

Youdim MB (2013) Multi target neuroprotective and neurorestorative anti‐Parkinson and anti‐Alzheimer drugs ladostigil and m30 derived from rasagiline. Experimental Neurobiology 22: 1–10.

Further Reading

Handler Norbert and Buschmann Helmut (2018) Drug Selectivity: An Enveloping Concept in Medicinal Chemistry: Weinheim, Germany.

Morphy J Richard and Harris C John (2012) Designing Multi‐Target Drugs: Cambridge, UK.

Peters Jens‐Uwe (2012) Polypharmacology in Drug Discovery: New Jersey, USA.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Bolognesi, Maria L, and Rossi, Michele(Feb 2020) Multitarget Drug Discovery. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0028845]